BELIMUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A REAL-LIFE EXPERIENCE

2016 ◽  
Author(s):  
Juan Camilo Sarmiento-Monroy
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Life Experience ◽  
Real Life ◽  
Systemic Lupus

Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients

2016 ◽  
Vol 35 (7) ◽  
pp. 1719-1723 ◽  
Author(s):  
Morton Scheinberg ◽  
Flavio Fernando Nogueira de Melo ◽  
Adrian Nogueira Bueno ◽  
Carolyne Mendes Costa ◽  
Maria Lucia Alvares de Azevedo Bahr ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Trials ◽  
Lupus Erythematosus ◽  
Life Experience ◽  
Real Life ◽  
Systemic Lupus

scholarly journals Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience

RMD Open ◽  
2019 ◽  
Vol 5 (2) ◽  
pp. e000916 ◽  
Author(s):  
Chiara Tani ◽  
Elena Elefante ◽  
Viola Signorini ◽  
Dina Zucchi ◽  
Valentina Lorenzoni ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Life Experience ◽  
Real Life ◽  
Patient Characteristics ◽  
Systemic Lupus ◽  
Low Disease Activity ◽  
Treatment Information ◽  
Asian Pacific

ObjectivesTo evaluate the proportion of patients who have successfully withdrawn glucocorticoids (GCs) in a longitudinal cohort of patients with systemic lupus erythematosus (SLE) over a period of 6 years; to evaluate patient characteristics during GC withdrawal in relation to existing definitions of remission and Lupus Low Disease Activity State (LLDAS); and to evaluate the occurrence of flares after GC withdrawal.MethodsPatients who attempted GC withdrawal were identified for the cohort, and the following information was assessed during withdrawal attempts: date of last disease flare, disease activity and damage and ongoing treatment. Information regarding the occurrence of disease flares after GC withdrawal was also recorded for patients who successfully stopped treatment.Definitions of remission were applied to GC withdrawal in line with European consensus criteria (Definitions of remission in SLE [DORIS]) and LLDAS in line with the Asian Pacific Lupus Consortium definition.Results148 patients were involved in the study; GC withdrawal was attempted in 91 patients (61.5%) with 77 patients (84.6%) successfully stopping GCs. At the beginning of the GC reduction, the majority of patients were in complete or clinical remission (48.9% and 39.6%, respectively). Disease activity was significantly lower in patients who successfully stopped GCs, and the proportion of patients in complete remission was higher (54.2%) with respect to patients who failed in their attempt. Among patients who stopped GCs, 18 flares were recorded after a median of 1 year. The time period since the last flare was shorter in patients who experienced flares with respect to patients who did not flare (mean 0.93 years vs 6.0, p<0.001).ConclusionsGC withdrawal is an achievable goal in SLE and may be attempted after a long-term remission or LLDAS to protect the patient from disease flares.

THU0290 Twelve Months Survival Rate and Causes of Withdrawal of Belimumab in Systemic Lupus Erythematosus in A Real Life Setting

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 291.3-292
Author(s):  
F.R. Spinelli ◽  
F. Ceccarelli ◽  
F. Morello ◽  
L. Massaro ◽  
C. Alessandri ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Survival Rate ◽  
Lupus Erythematosus ◽  
Real Life ◽  
Systemic Lupus ◽  
Real Life Setting
Sign in / Sign up

Export Citation Format

Share Document